Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Eli Lilly

It's Not Time To Buy. But These Stocks Flash 'Watch Me' Signs.

As the market turmoil deepens, here are two telltale indicators to track as investors adjust their lists of stocks to watch.

Investors Business Daily

Meta, Netflix Hold Tough As Tech Tanks. This Biotech Booms.

Meta, Netflix Hold Tough As Tech Tanks. This Biotech Booms.

While Netflix and Meta stock fight to shake off market volatility, Eli Lilly and this biotech stock join them and others on IBD Leaderboard.

Investors Business Daily

Is Johnson & Johnson Stock Underperforming the Dow?

Is Johnson & Johnson Stock Underperforming the Dow?

Despite Johnson & Johnson’s underperformance relative to the Dow over the past year, Wall Street analysts maintain a moderately optimistic outlook on the stock’s prospects.

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Is Eli Lilly Stock Outperforming the Nasdaq?

Eli Lilly has outperformed the Nasdaq over the past year, and analysts are highly optimistic about the stock’s prospects.

How To Buy And Sell Stocks: This Table Finds Important Stock Moves

How To Buy And Sell Stocks: Use this IBD table to find stocks that are moving up and down in heavy volume on the stock market today.

Investors Business Daily

Is This Penny Stock’s 525% Upside Potential an Attainable Goal?

Skye Bioscience is trying to establish a presence in the weight-loss drug market.

3 Pharmaceutical Stocks Betting Big on Weight Loss Drugs

Weight-loss drugs aren’t just slimming waists; they create a $100 billion market opportunity. With plenty up for grabs, pharmaceutical giants like Eli Lilly and Company (LLY), Novo Nordisk (NVO), and Amgen (AMGN) are betting big on next-generation weight loss treatments to dominate this booming market. Keeping reading.

inkl

Read news from The Economist, FT, and more,
with one subscription

Eli Lilly Joins Rank Of Stocks With 95-Plus Composite Rating

Eli Lilly Joins Rank Of Stocks With 95-Plus Composite Rating

Eli Lilly saw its IBD SmartSelect Composite Rating jump to 96 Tuesday, up from 94 the day before.

Investors Business Daily

Hims Stock Crashes After FDA Resolves Weight-Loss Drugs Shortage

Hims Stock Crashes After FDA Resolves Weight-Loss Drugs Shortage

HIMS stock fell after the FDA said the shortages in Novo Nordisk's weight-loss drug has been resolved.

Investors Business Daily

Weight-loss drug Zepbound helped Ireland ship $76bn in goods to the U.S.

Weight-loss drug Zepbound helped Ireland ship $76bn in goods to the U.S.

Ireland's pharmaceutical industry shipped billions' worth of goods to the U.S., but face threats from Trump 2.0.

Will Eli Lilly Stock Keep Climbing? Q2 Trial Results Are Crucial

Will Eli Lilly Stock Keep Climbing? Q2 Trial Results Are Crucial

Eli Lilly is still seeing rapid sales growth for its diabetes and weight loss drugs. However, one drug waiting in the wings hopes to be its next blockbuster.

These Stocks Missed on Earnings, But Will Rebound Next Quarter

These Stocks Missed on Earnings, But Will Rebound Next Quarter

Here are three stocks from companies that missed on earnings but have strong support from analysts that makes each stock a solid Buy for the next year

Stock Market Sideways Amid Trump Tariff, Inflation Fears; Palantir, Google, Amazon Among Key Movers: Weekly Review

Stock Market Sideways Amid Trump Tariff, Inflation Fears; Palantir, Google, Amazon Among Key Movers: Weekly Review

The stock market was up and down with Trump tariff fears in focus. Palantir led big earnings winners. Google and Amazon were losers.

Investors Business Daily

What Are Wall Street Analysts' Target Price for Eli Lilly Stock?

What Are Wall Street Analysts' Target Price for Eli Lilly Stock?

As Eli Lilly has outperformed the broader market over the past year, Wall Street analysts maintain a bullish outlook on the stock’s prospects.

Get all your
news in one place.

100’s of premium titles.
One news app.

Eli Lilly Stock Rises After Profit, Outlook Top Expectations

Eli Lilly stock is higher Thursday after the pharma giant beat fourth-quarter profit expectations and issued strong 2025 guidance. Here's what you need to know.

The Independent UK

Diabetes and obesity drugs fuel Eli Lilly profit in the final quarter of 2024

Eli Lilly’s profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments, and the drugmaker debuted a mostly better-than-expected 2025 forecast

Investors Business Daily

Dow Jones Rises After Surprise Jobless Claims; Roblox Crashes 30% On Sales Miss

The Dow Jones rose Thursday after surprise weekly jobless claims. Nvidia partner Arm stock tumbled on earnings, while Roblox crashed.

Investors Business Daily

Eli Lilly Jumps, Reversing Its Weight-Loss Setback, On A Strong 2025 Outlook

Eli Lilly stock rose Thursday despite lighter-than-expected sales of its weight-loss and diabetes drugs Zepbound and Mounjaro.

Get all your
news in one place.

100’s of premium titles.
One news app.

Stocks Muted Before the Open With Focus on U.S. Economic Data and Amazon Earnings

March S&P 500 E-Mini futures (ESH25) are up +0.05%, and March Nasdaq 100 E-Mini futures (NQH25) are down -0.08% this morning as investors awaited a new round of U.S. economic data, remarks from Federal Reserve officials, and an earnings report from “Magnificent Seven” member Amazon.

Stocks Rise Before the Open With Focus on U.S. Economic Data and Amazon Earnings

March S&P 500 E-Mini futures (ESH25) are up +0.20%, and March Nasdaq 100 E-Mini futures (NQH25) are up +0.10% this morning, suggesting Wall Street is set to extend yesterday’s gains, while investors awaited a new round of U.S. economic data, remarks from Federal Reserve officials, and an earnings report from…

Investors Business Daily

Eli Lilly Shows Rising Relative Price Performance; Still Shy Of Key Benchmark

A Relative Strength Rating upgrade for Eli Lilly shows improving technical performance. Will it continue?

The faulty forecasts of pharma firm investors: Misguided cynics miss the promising prognosis for drugmakers Pfizer and Merck

Pfizer and Merck, ostensibly beleaguered drugmakers, have seen their shares battered despite reporting strong earnings.

Investors grow anxious at Novo Nordisk's silence over CagriSema weight loss results

Investors are upset at a lack of clarity over the results of Wegovy successor CagriSema after trials published in December.

Apple, Nvidia, and more of the 2025 World's Most Admired Companies

Plus: How AI propelled Nvidia up the list and other insights from this year's survey of corporate reputations.

This Little-Known Stock Just Doubled on Weight-Loss Drug News. Analysts Think It Has 400% Upside Potential From Here.

This weight-loss underdog doubled in a single day last week and could deliver even bigger rewards.

People

124,564 stories

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

US Federal Reserve

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

283,434 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play